

The Case for a Designated Clinical Research Educator

CANCER CENTER

Purpose

In a busy clinical trials office with more than 80 staff members, it may be daunting to onboard new staff with the goal of ensuring continued education of current regulations and best practices related to clinical research. This proves particularly challenging given that it is rare that new staff have any previous clinical research experience or a high level of relevant knowledge. Consistency in training (i.e., internal processes and expectations, best practices, etc.) is often also a hurdle. By having designated Clinical Research Educators (CREs), MCW's Cancer Center Clinical Trials Office has been able to provide uniform training across specialties leading to improved adherence to performance expectations and consistent best practices across teams.

Methods and Materials

The cancer center CREs provide ongoing education to staff through an onboarding program, which is tailored by position; monthly education seminars; an annual symposium and other specific trainings, as applicable. Methods of teaching include didactic methods, as well as hands-on learning and simulation. The educators also create tools and checklists with the goal of developing uniform intra-department processes. Another unique duty of a cancer center CRE is to assist in distributing and developing learning opportunities that meet continuing education requirements for staff maintaining professional research certifications. This reduces a major burden for staff members (finding applicable courses, obtaining funding/reimbursement, dedicating travel time, etc.), and provides all staff with continued learning opportunities. The CREs also assist staff in preparation for audits and the development of Corrective and Preventative Action Plans.

Results

Utilizing dedicated CREs has had a positive impact in the MCW Cancer Center Clinical Trials Office in many areas. For example, during the orientation phase, new staff feel supported by having a main contact and they experience a much smoother and consistent onboarding process when CREs coordinate a majority of the process. This simultaneously decreases the onboarding burden of our experienced staff and reduces variations in training. In addition, audit outcomes have improved significantly as departmental standards and best practices have been developed and enforced. This includes fewer major and minor findings and auditors praising the consistency of documentation practices. The monthly educational opportunities developed by CREs have made it easier for staff to obtain educational credits and maintain their research certifications. Educators also have become resources to our entire department beyond the onboarding process by developing standard operating procedures and guidelines, and providing day-to-day assistance as needed (i.e., troubleshooting, facilitating questions regarding internal processes, required trainings, etc.).

Conclusions & Discussion

The implementation of CREs has proven to be a successful model for the MCW Cancer Center Clinical Trials Office. Other departments have sought out the CREs as resources for their own staff training and education. Our CREs also have collaborated on campuswide education initiatives. Having designated educators has promoted a consistent culture of clinical research best practices within the MCW Cancer Center Clinical Trials Office.

Acknowledgements

Special thanks to Ms. Carrie O'Connor for her technical writing assistance on this poster.

Maraty Gray, BA, CCRP; Rebecca Selle, BS, CCRP; Betty Oleson, BSN, RN, CCRP; James Thomas, MD, PhD - Medical College of Wisconsin

			_							
PRE-SCREENING: OnCore/EPIC			ENROLLED/START OF TREATMENT							
OnCore				Date enrolled to stu	ly					
OnCore Pre-Screening Number				Treatment start date						
Date patient entered into OnCore Pre-Scree	er			Patient Study ID nur	nbe					
OnCore Patient Contact Date						OnCore				_
EPIC				All OnCore Pre-Scre	ening inf	ormation completed				Yes
Protocol added to EPIC Research Activity ta EPIC research status identified added		□ N/A		Eligibility Tab Compl Version Date (protocol v), Verified By (2nd reviewer)	, Status Date (d	late enrolle	d)	Ves
CRC Initials/Date: Manager/DTL/Date				On Study Tab: Subje Sequence # (study ID #)		udy Completed: late (date enrolled), zip code	2			Yes
CONSENT Date Consent Signed				On Study Tab: Subj	ect Staff (-		l already be	added)	Ves
Consent Process Documented		Yes		Treatment Tab Com	leted:	eatment Date (date treatmer				Yes
Copy of consent with labels attached Date ICF emailed to Compliance & Manager		Yes		Transplant (if applical DP/ECN		Chemotherapy (Conditionin	-	Transplant D	late:	□ N/A
OnCore			_							_
Protocol Version Date						EPIC				1_
Treating Physician						rview comment: see FYI Fla	g)			
Updated Pre-Screening/Added Subject to F	Protocol	Yes		Add FYI Flag (use ".C	-					
OnCore Consent Tab Completed		Yes		EPIC Research State						
OnCore Study Tab Updates Completed		Yes		Clinic staff notified a	and educa	ation note documented	l (CC CTO Edu	cation sma	rtphrase)	Yes
EPIC										
EPIC Research Status reflects Consented	Yes	N/A	C	RC Initials/Date:		Manager/D	TL/Date:			
Manager comments:				ELIGIBILITY					Primary CRC	2nd CBC
CRC Initials/Date: Manager/DTL/Date				IRB Approve			Stamp Date	•=		
					-	atient, MD/CRC/Nurse sign	, dates match)			Ves
PRE-SCREEN/SCREEN FAIL			_	Consent Process Do						
OnCore						lures are completed?				
Date of Pre-screen/Screen fail				All eligibility questio						
Pre-Screening/Eligibility updated		Yes		Documentation of e		priteria?				
Pre-screen/Screen Fail reason documented				Patient eligible for p						
Pre-screen subject note/Eligibility reason c	omment a	a Ves		Physician signed/da	ted proto	col eligibility				
Reason comment:										
If consented, OnCore Eligibility Tab Complet	te 🗌 Yes	N/A	P	rimary CRC/Date:			Secondary CR	C/Date:		
EPIC										
EPIC Research Status updated, please circl	le: Decli	Yes	N	/lanager/Date:						

	enera Or Ge Th Or Tra so ⁻ An Do Re Pre Sh Se
	eeks Elec IRB Info Wor Wor
	eeks Nev

Subject Initials: <u>K</u> P K

180.0

Figure 1: Checklist for new subject screening and enrollment reflecting internal workflows



Staff Training & Competency Form

Gender	Male Female	Weight (kg)	093.50
MEDICAL HISTORY			
Date of Assessment (dd/mm/yyyy)	18/06/20	17	Not done
Blood pressure (mmHg)	136/078	Temperature (°C)	36.80
Pulse	69	Respiration (/min)	18
LABS			
Creatinine	Date (dd/mm/yyyy):	106/2017	D .99 _{mg/dL}
Alkaline phosphatase	Date (dd/mm/yyyy):	106/2017	5 4 unit/L
PATHOLOGY	V		
	Adenocarcinoma		
	Urothelial		
	Squamous cell		
Diagnosis SUBJECT ELIGIBILITY	Small cell		
	BASELINE	MEDICAL HISTORY	
Condition		Start Date (dd/mm/yyyy)	
Hyperlipi	demia	01/01/20	011
Sleep apr	iea	UK/UK/20	12
Hypert	ension	01/01/20	211
J,			
		LABS	
Date of Assessment	(dd/mm/yyyy):		017
Alkaline Phosphatase	54.00	(Sent) Xunit/L	als totate
		0	

FLIGIBILITY CR

We	eeks
	Nev
	IRB
4-6	5 ma
	Rev
	_
	Δςς

Figure 4:	
-----------	--

Figure 2: Competency assessment example for regulatory coordinators/specialists

Figure 3: Answer keys to exercises for data entry, documentation, and eligibility

□mg/dL Xunit/L □mmol/L

□mg/dL Xunit/L □mmol/L

Xmg/dL □unit/L □mmol/L

□mg/dL □unit/L Xmmol/L

Img/dL Iunit/L Mmmol/L

⊠mg/dL □unit/L □mmol/L

Kmg/dL - Kunit/L Ommol/L

35.00 37.00

71.99

04.70

27.00

09.90

00.80

Glucose

Potassium

Bicarbonate

DEMOGRAPH 12/02/1955 Height (cm) Date of birth (dd/mm/yyyy)

Onboarding Curriculum

All Staff

ral topics (Weeks 1-2)

ncology and clinical trials basics

eneral workflows and ancillary services

ne flow of a new study (e.g., Confidentiality Disclosure Agreements, Disease riented Team, Scientific Review Committee, DSMC, etc.)

raining for the Clinical Trial Management System and other applicable oftware/databases

natomy of a protocol and source documentation

ocumentation per GCP, FDA regulations, and internal expectations

eview department Standard Operating Procedures and guidelines receptor assignment

nadowing opportunities (e.g., Translational Research Unit, Investigational Drug

ervices (IDS), research lab staff, etc.)

Clinical Research Assistants, Coordinators, and Nurses

2-3

ectronic Medical Record training including oncology specific workflows 8 reporting

ormed consent process

orkflows for subject screening, enrollment, and study visits

orkflows with ancillary departments (e.g., compliance, imaging, lab, IDS, etc.)

Regulatory Coordinators and Specialists

2-3

w study submission process including:

□ IRB submission

□ Workflows with ancillary departments (e.g., safety committees, budget and contract team, compliance, etc.)

□ Informed Consent Form preparation

Execution of essential documents

Guidance in working with sponsors and Clinical Research Organizations

submissions of amendments, annual reviews, and reportable events

Competency Evaluations

onths into employment

view a subject shadow chart or regulatory binder completed by new staff Assess independence and proficiency of workflows and tasks covered during onboarding

: Abbreviated onboarding curriculum checklist

Contact

Maraty T. Gray, BA, CCRP Medical College of Wisconsin mtgray@mcw.edu www.mcw.edu/Cancer-Center.htm 414-805-8244